Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

News Follows Medtronic Receiving FDA Breakthrough Device Designation for its Valiant Navion™ LSA Branch Thoracic Stent Graft System News Follows Medtronic Receiving FDA Breakthrough Device Designation for its Valiant Navion™ LSA Branch Thoracic Stent Graft System

Medtronic Receives FDA Breakthrough Device Designation for Developing Stent Graft System to Treat Thoracoabdominal Aortic Aneurysm

Pivotal Software

Study to Evaluate Novel Implantable Defibrillator System with a Lead Placed Outside the Heart and Veins Study to Evaluate Novel Implantable Defibrillator System with a Lead Placed Outside the Heart and Veins

Medtronic Initiates Worldwide Pivotal Study of a New Approach to Treating Dangerously Fast Heart Rhythms

Smaller, Rechargeable Device Will Provide More Choices for Patients Suffering with   Bladder and Bowel Control Issues

Medtronic Announces FDA Submission for InterStim™ Micro Neurostimulator and SureScan™ MRI Leads

Capri Holdings Ltd

TriNet Group

V.F.

Wendy's

CNBC combed through recent Wall Street research to find stocks that analysts say may have been "overlooked."

These stocks have 'overlooked' stories, Wall Street analysts say

Abbott Labs

Texas Instruments

The stocks of companies with CEOs who are founders can be big winners. But so can the stocks of companies that aren't led by their founders.

3 Great Dividend Stocks That Aren't Founder-Led

Accuray

Intuitive Surgical

Stereotaxis Inc

Stryker

Varian Medical Systems

Accuray and Stereotaxis are hyper-focused on growth.

High-Tech Robotic Surgery Gets Specialized

Medtronic’s revenue has grown around 6% over the last three years. This can be attributed to steady growth in its Restorative Therapies Group, Cardiac & Vascular Group, and Diabetes Group, partly offset by a decline in the Minimally Invasive Therapies Group, due to certain divestures.

What’s Driving Medtronic’s Revenue Growth?

Medtronic's (MDT) DAPT study's robust data outcome is likely to aid as the therapy duration might prove to be a superior treatment option.

Medtronic Upbeat on Drug-Eluting Stents in Patients With DAPT

The FDA clearance is expected to boost Medtronic's (MDT) structural heart business.

Medtronic (MDT) Gets FDA Nod to Study Intrepid TMVR System

Within Diabetes group, Medtronic (MDT) is seeing a strong adoption of the Guardian Connect Smart CGM system.

Medtronic's All Business Lines Grow Despite Cost Concerns

New Study Shows Momentum in Establishing a Less Invasive Approach to Treat Patients with Severe Mitral Valve Disease New Study Shows Momentum in Establishing a Less Invasive Approach to Treat Patients with Severe Mitral Valve Disease

Medtronic Announces Early Feasibility Trial for Intrepid™ Transcatheter Mitral Valve Replacement System with Transfemoral Transseptal Approach

TCT19: First Results from Onyx ONE Global Study Also Show Superior Acute Performance and Build Upon Robust Clinical Evidence for Resolute Onyx with Shortened DAPT TCT19: First Results from Onyx ONE Global Study Also Show Superior Acute Performance and Build Upon Robust Clinical Evidence for Resolute Onyx with Shortened DAPT

Resolute Onyx™ DES Meets Primary Endpoint in First-Ever Clinical Study Comparing Drug-Eluting Stents in High-Bleeding Risk (HBR) Patients with One-Month DAPT

Emerging market countries present lucrative prospects; consequently, investors can take a look at the space.

3 MedTech Stocks in Focus on Emerging Market Prospects

Arch Capital

DocuSign

Johnson Controls

Royal Bank of Canada

According to GuruFocus list of 52-week highs , these Guru stocks have reached their 52-week highs.

5 Companies Hit 52-Week Highs.

This latest FDA approval of Medtronic's (MDT) Evolut PRO+ follows the last month's nod from the regulatory body for the Evolut TAVR system with regard to expanded indication.

FDA Nods to Medtronic's (MDT) New Age Evolut PRO+ TAVR

Medtronic Surgical Synergy(SM) is Advanced with Range of New Procedural Solutions Unveiled at NASS 2019

Medtronic's (MDT) MiniMed 670G system boasts a special feature of SmartGuard Auto Mode that improves Time in Range.

Medtronic's MiniMed 670G Shows Favorable Outcome in Europe

Improved Functionality Across Four Valve Sizes and Lowest Delivery Profile on the Market, the Evolut PRO+ TAVR System Launches in U.S. as TAVR Patient Population Grows Improved Functionality Across Four Valve Sizes and Lowest Delivery Profile on the Market, the Evolut PRO+ TAVR System Launches in U.S. as TAVR Patient Population Grows

Medtronic Announces FDA Approval and U.S. Launch of Next-Generation Evolut™ PRO+ TAVR System for Treatment of Symptomatic Severe Aortic Stenosis Patients

Medtronic (MDT) reported earnings 30 days ago. What's next for the stock?

Why Is Medtronic (MDT) Up 2.1% Since Last Earnings Report?

Medtronic (MDT) plans to upgrade diabetes care by combining technical advancement with better user experience.

Medtronic Receives European Nod for Glucose Monitoring System

A number of MedTech companies are currently attempting to gain ground within the robotics-aided healthcare market.

The Rise of Robots in Surgery Puts Spotlight on These 3 Stocks

DUBLIN, Sept.  18, 2019  (GLOBE NEWSWIRE) --  Medtronic plc  (NYSE:MDT), the global leader in medical technology, services and solutions today announced real-world clinical outcomes on European patients for the MiniMed™ 670G system. The European data showed an average Time in Range of 73%1, a result that exceeds the recommended Time in Range consensus guidelines of 70% that were recently published2. The real-world data of 4,369 patients showed an average estimated HbA1c of 6.9%*1, also surpasses the recommended target.3

MiniMed™ 670G System European Real-World Data Shows 73% Time in Range, Beyond Recommended Targets

Novo Nordisk

This collaboration is expected to boost Medtronic's (MDT) diabetes management portfolio.

Medtronic Collaborates With Novo Nordisk for Diabetes Care

Next-Generation Professional CGM Combines Valuable Data with Optimal User Experience Next-Generation Professional CGM Combines Valuable Data with Optimal User Experience

Medtronic Introduces Envision™ Pro Continuous Glucose Monitoring (CGM) System in Europe

DUBLIN, Sept.  16, 2019  (GLOBE NEWSWIRE) --  Medtronic plc  (NYSE:MDT), the global leader in medical technology, today announced that it will host aRobotic-Assisted Surgery (RAS) Investor Update on Tuesday, September 24, 2019, in Hartford, Conn., from 2:00 p.m. to approximately 5:30 p.m. Eastern Daylight Time. The update will include a robotic-assisted surgical procedure performed in a lab as part of the Medtronic Minimally Invasive Therapy Group’s ongoing development and testing process of its RAS technology. In addition, the update will include remarks and responses to audience questions from a panel of surgeons and Medtronic management. Management Q&A is scheduled to begin at approximately 4:15 p.m. Eastern Daylight Time, or shortly thereafter. Medtronic’s RAS technology is currently under development. The device is not cleared or approved in the U.S. or any market.

News for Medtronic Stock (MDT)